chondroitin sulfate + sodium hyaluronate (Pierre Fabre)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namechondroitin sulfate + sodium hyaluronate (Pierre Fabre)
Drug Alias NameV-0220
ClassificationSmall molecules > Carbohydrate > Oligosaccharide
Mechanisms of ActionHyaluronic acid modulatorsN-acetylgalactosamine-6-sulfatase modulators
TargetsHyaluronic acidN-acetylgalactosamine-6-sulfatase
Therapy Area/IndicationsOsteoarthritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsYes
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPierre Fabre Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPierre Fabre Ltd
Active IndicationsN/A
Inactive IndicationsOsteoarthritis

Other Information

ATC CodeN/A
Related LinksN/A